Waddell & Associates’s Pfizer PFE Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q2
$966K Buy
40,111
+12,898
+47% +$337K 0.05% 139
2026
Q1
$764K Buy
27,213
+1,403
+5% +$37.4K 0.04% 145
2025
Q4
$643K Buy
25,810
+1,532
+6% +$38.6K 0.04% 129
2025
Q3
$619K Buy
24,278
+1,660
+7% +$41K 0.05% 111
2025
Q2
$548K Buy
22,618
+95
+0.4% +$2.22K 0.06% 102
2025
Q1
$571K Sell
22,523
-2,484
-10% -$65K 0.07% 74
2024
Q4
$663K Buy
25,007
+29
+0.1% +$787 0.07% 71
2024
Q3
$723K Buy
24,978
+388
+2% +$11.3K 0.09% 64
2024
Q2
$688K Buy
24,590
+11,547
+89% +$318K 0.09% 65
2024
Q1
$362K Sell
13,043
-7,651
-37% -$212K 0.05% 92
2023
Q4
$601K Sell
20,694
-13,772
-40% -$416K 0.08% 68
2023
Q3
$1.14M Buy
34,466
+85
+0.2% +$3.01K 0.17% 51
2023
Q2
$1.26M Sell
34,381
-2,567
-7% -$99.9K 0.19% 44
2023
Q1
$1.51M Buy
36,948
+1,964
+6% +$84.8K 0.24% 37
2022
Q4
$1.79M Buy
34,984
+329
+0.9% +$15.8K 0.3% 33
2022
Q3
$1.52M Buy
34,655
+44
+0.1% +$2.14K 0.29% 31
2022
Q2
$1.81M Sell
34,611
-21
-0.1% -$1.07K 0.37% 22
2022
Q1
$1.79M Buy
34,632
+1,923
+6% +$99.8K 0.29% 24
2021
Q4
$1.93M Buy
32,709
+3,610
+12% +$179K 0.31% 22
2021
Q3
$1.25M Sell
29,099
-652
-2% -$28.9K 0.21% 33
2021
Q2
$1.17K Buy
+29,751
New +$1.16M 0.18% 26

Other funds holding PFE

Waddell & Associates's PFE Position: Q2 2026 in Review

Waddell & Associates increased its Pfizer (PFE) stake by 47% in Q2 2026, buying an estimated $337K and bringing the position to 40,111 shares worth $966K. The position accounts for 0.05% of the portfolio, ranked #139.

Waddell & Associates first reported a position in PFE in Q2 2021 and has held it in 21 quarters since. The position peaked at $1.93M in Q4 2021. 1,005 funds tracked by Wall St. Rank hold PFE as of Q2 2026.

  • Waddell & Associates held 40,111 shares of Pfizer worth $966K as of Q2 2026.
  • Waddell & Associates bought 12,898 Pfizer shares in Q2 2026, an estimated $337K.
  • Pfizer made up 0.05% of Waddell & Associates's portfolio in Q2 2026, its #139 holding.
  • Waddell & Associates first reported a position in Pfizer in Q2 2021 and has held it in 21 quarters since.
  • Waddell & Associates's Pfizer position peaked at $1.93M in Q4 2021.
  • 1,005 funds tracked by Wall St. Rank held Pfizer as of Q2 2026.

Based on Waddell & Associates's 13F filing for Q2 2026, filed 15 Jul 2026.